Navigation Links
SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
Date:8/26/2008

any's focus - cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN. The company has successfully discovered and is developing a portfolio of drug candidates addressing these targets.

About SF1126

There is a strong and significant biological rationale for developing PI3 kinase inhibitors to treat cancer. Phosphoinositide 3-kinase (PI3K) is the gate keeper of one of the major pathways of intracellular signal transduction that regulates cell growth, proliferation, angiogenesis, migration, differentiation, and survival. Dysregulation of the PI3K signaling pathway is believed to play an integral role in the genesis of many cancers including both solid tumors and hematologic malignancies. Cancer research and pharmaceutical drug development efforts have been aimed at discovering and developing therapeutics that inhibit PI3K with the hope of controlling cancer cell division, angiogenesis (the formation of new blood vessels for cancer

growth), proliferation and metastasis. Semafore's innovative PI3K inhibitor, SF1126, promises such hope for cancer patients.

SF1126, is a proprietary small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including mTOR, DNA-PK, PLK-1,CK2, ATM and PIM-1 kinases all known to be involved in the cascade of chemical signals that control cell division. Importantly, SF1126 is designed as a dual inhibitor of both angiogenesis and cell proliferation. SF1126 is engineered to target and bind to specific integrins (alpha gamma beta 3) that are expressed on the surface of new tumor vasculature and within the tumor endothelial compartment. In tumor xenograph models Semafore demonstrated enhanced drug uptake of SF1126 which was directly attributable to the alpha gamma beta 3 targeted moiety. SF1126 is water soluble, has favorable pharmacok
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
3. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
4. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
5. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
6. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
7. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
8. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
9. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
10. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Come fall, many children, teenagers, and ... they want to be for Halloween. And, a number ... decorative contact lenses bought without a prescription. ... people purchase and wear contact lenses without a prescription. ... ® consumer survey, 17 percent of Americans have ...
(Date:9/30/2014)... Sept. 30, 2014 Chindex ... CHDX ) today announced the completion of its acquisition ... per share in cash.  Healthy Harmony is an affiliate ... and Ms. Roberta Lipson , the CEO of ... was adopted by Chindex,s stockholders at a special meeting ...
(Date:9/30/2014)... CARLOS, Calif. , Sept. 30, 2014 /PRNewswire/ ... an additional $10 million investment from current investors ... The additional financing was completed following achievement of ... lead antibody program, and represents an extension of ... closed in December 2012. With this additional financing, ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4
... BALTIMORE, May 5, 2011 New data presented ... Interventions (SCAI) Scientific Sessions are the first to ... within implantable cardioverter defibrillators (ICDs) to detect restricted ... disease patients outside the hospital setting. Preliminary results ...
... 5, 2011 Echo Therapeutics, Inc. (OTCBB: ECTE), a ... wireless, transdermal continuous glucose monitoring (tCGM) system and the ... the relocation of its corporate headquarters from Franklin, MA ... located in the heart of Philadelphia,s Center City Business ...
Cached Medicine Technology:New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 2New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 3Echo Therapeutics Expands Into New Headquarters in Philadelphia 2
(Date:9/30/2014)... 2014 Lea Blackwell, M.D., a Breast ... patients a new, more practical and comfortable option for ... mastectomies, biopsies and lumpectomy surgeries use special bras after ... seeing her patients describe the bra as scratchy, uncomfortable ... new bra in her spare time. , Ilona ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... to reach USD 8,020.1 million by 2020, according ... Inc. Growing demand for personalized medicine and theranostics, ... technologies are expected to be key factors driving ... the growing global base of geriatric population and ...
(Date:9/30/2014)... During this online virtual event, hear ... including achieving hormonal balance, relieving menopause symptoms, breast ... , The details of the virtual ... 2014, Location: Online Event, Registration: Complimentary , Visit ... Monday, October 6th, Steven F. Hotze, M.D., David ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... ADVISORY** , From:        Hope For ... 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org , ... Celebration , Date:        Thursday, October ... Army and Navy Club, ...
Breaking Medicine News(10 mins):Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2
... American Oriental,Bioengineering, Inc. (NYSE: AOB ), ... nutraceutical products in China, today,announced that the Company ... Company will present at the CIBC World Markets ... at the Waldorf-Astoria,Hotel in New York City. Management ...
... Now Able to Submit Aetna Claims at No Cost ... Inc., a leading,healthcare technology company focused on providing innovative ... today,announced it has expanded its relationship with Aetna to ... 1, 2007. Aetna is a leading,diversified health care benefits ...
... Health Care Costs, DALLAS, Oct. 26 ... M.D., M.P.H., Cooper Aerobics Enterprises,Inc., announced today its ... Enterprises purchased Health At Work, a licensed,health, life ... Cooper Benefits,LLC. Cooper Benefits merges traditional employee ...
... WEST BERLIN, N.J., Oct. 26 EP MedSystems,(Nasdaq: EPMD ) announces the following ... 11/01/2007 @ 4:30 pm EST, Where: ... Simply log on to the web at the ... person of EP MedSystems, ...
... Jack Group, Inc.,(MattsonJack) announces the release of its ... help clients make strategic,decisions based on an in-depth ... conditions. Comorbidity Database(TM) consists of,two modules: Comorbidity Database(TM) ... and Comorbidity Database(TM) -- Med 2.0, which features ...
... Institutet have shown that hysterectomy a common operation ... the risk of urinary incontinence. Their results, which ... Lancet. , Hysterectomy is the most common gynaecological ... as a cure for benign medical problems in order ...
Cached Medicine News:Health News:American Oriental Bioengineering Announces Participation in November Healthcare Conferences 2Health News:MD On-Line Expands Relationship with Aetna for Direct Claim Submission 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 3Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 4Health News:Webcast Alert: EP MedSystems Announces EP MedSystems Third Quarter 2007 Earnings Conference Call Webcast 2Health News:The Mattson Jack Group, Inc. Announces the Release of the New Comorbidity Database(TM) 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: